Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gusperimus

A derivative of the antitumor antibiotic spergualin with immunosuppressant activity. Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:deoxyspergualin
Deoxyspergualin Hydrochloride
Gusperimus Trihydrochloride
Foreign brand name:Spanidin
Abbreviation:DSG
Code name:BMS-181173
BMY-42215-1
NKT-01
Chemical structure:1-amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione
15-deoxyspergualin hydrochloride
7-{(aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amnio]-1-hydroxy-2-oxoethyl]heptanamide
N-[[[4-[(3-Aminopropyl)amino]-butyl]carbamoyl]hydroxymethyl]-7-guanidinoheptanamide
IND number:28053
NSC code:356894
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search